Immunome's Stock Jumps On Its Antibody Cocktail Neutralizing Multiple COVID-19 Variants In Animal Studies

Immunome Inc IMNM has announced antibody selection for its IMM-BCP-01 antibody cocktail and shared preclinical data showing that IMM-BCP-01 is effective against the current SARS-CoV-2 and its variants.
In Syrian hamsters infected with live SARS-CoV-2 virus, IMM-BCP-01 reduced lung viral load as a treatment and prophylaxis.
Data also demonstrated full neutralization by IMM-BCP-01 of emerging/concerning variants of COVID-19 and mutations.
Mechanistic studies demonstrate that the selected antibodies bind not only to SARS-CoV-2 spike proteins with complex mutations but also to those with several individual mutations.
Two of the three selected antibodies bind to areas of the Spike protein that may be resistant to evolutionary change.
Immunome anticipates filing an IND for its IMM-BCP-001 program in late Q2/early Q3 2021.
IMM-BCP-01 contains three monoclonal antibodies that bind to non-overlapping regions of the spike protein with picomolar affinity.
Price Action: IMNM shares are trading 12.7% higher at $33.29 in the premarket session on the last check Monday.